7494 results
Cited 62 times since 2023 (20.9 per year)
source: EuropePMC
European heart journal,
Volume 44, Issue 3, 1 1 2023, Pages 176-177
The '10 commandments' for the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
Tfelt-Hansen J, Winkel BG, de Riva M, Zeppenfeld K
Abstract
Cited 3 times since 2023 (1 per year)
source: EuropePMC
Open research Europe,
Volume 3, 1 1 2023, Pages 82
The DECIDE project: from monitoring and surveillance data to decision-support for farmers and veterinarians.
van Schaik G, Hostens M, Faverjon C, Jensen DB, Kristensen AR, Ezanno P, Frössling J, Dórea F, Jensen BB, Carmo LP, Steeneveld W, Rushton J, Gilbert W, Bearth A, Siegrist M, Kaler J, Ripperger J, Siehler J, de Wit S, Garcia-Morante B, Segalés J, Pardon B, Bokma J, Nielen M
Farmers, veterinarians and other animal health managers in the livestock sector are currently missing sufficient information on the prevalence and burden of contagious endemic animal diseases. They need adequate tools for risk assessment and prioritization of control measures for these diseases. The DECIDE project develops data-driven decision-support tools, which present (i) robust and early signals of disease emergence and options for diagnostic confirmation; and (ii) options for controlling t...
Abstract
Cited 6 times since 2023 (2 per year)
source: EuropePMC
Journal of cardiovascular pharmacology and therapeutics,
Volume 28, 1 1 2023, Pages 10742484231210704
The Clinical Implementation of <i>CYP2C19</i> Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry.
Azzahhafi J, Broek WWAVD, Chan Pin Yin DRPP, Harmsze AM, van Schaik RHN, Ten Berg JM
Background: Guidelines recommend prasugrel or ticagrelor for acute coronary syndrome (ACS) patients. However, these P2Y12 inhibitors increase bleeding risk compared to clopidogrel. Although genotype-guided P2Y12-inhibitor selection has been shown to reduce bleeding risk, data on its clinical implementation is lacking. Methods: The study included ACS patients receiving genotype-guided antiplatelet therapy, utilising either a point-of-care (POC) device or laboratory-based testing. We aimed to coll...
Abstract
Cited 9 times since 2023 (3 per year)
source: EuropePMC
Age and ageing,
Volume 52, Issue 1, 1 1 2023, Pages afac312
Weight loss, visit-to-visit body weight variability and cognitive function in older individuals.
Zonneveld MH, Noordam R, Sabayan B, Stott DJ, Mooijaart SP, Blauw GJ, Jukema JW, Sattar N, Trompet S
Objective: to investigate the association between variability and loss of body weight with subsequent cognitive performance and activities of daily living in older individuals. Design: cross-sectional cohort study. Setting: PROspective Study of Pravastatin in the Elderly at Risk, multicentre trial with participants from Scotland, Ireland and the Netherlands. Subjects: 4,309 participants without severe cognitive dysfunction (mean age 75.1 years, standard deviation (SD) = 3.3), at higher risk for...
Abstract
Cited 32 times since 2023 (10.8 per year)
source: EuropePMC
Journal for immunotherapy of cancer,
Volume 11, Issue 1, 1 1 2023, Pages e005518
Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections.
van Puffelen JH, Novakovic B, van Emst L, Kooper D, Zuiverloon TCM, Oldenhof UTH, Witjes JA, Galesloot TE, Vrieling A, Aben KKH, Kiemeney LALM, Oosterwijk E, Netea MG, Boormans JL, van der Heijden AG, Joosten LAB, Vermeulen SH
Background: BCG is recommended as intravesical immunotherapy to reduce the risk of tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC). Currently, it is unknown whether intravesical BCG application induces trained immunity. Methods: The aim of this research was to determine whether BCG immunotherapy induces trained immunity in NMIBC patients. We conducted a prospective observational cohort study in 17 NMIBC patients scheduled for BCG therapy and measured trained immunity...
Abstract
Cited 106 times since 2023 (35.8 per year)
source: EuropePMC
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,
Volume 28, Issue 1, 1 1 2023
Increase in invasive group A streptococcal (<i>Streptococcus pyogenes</i>) infections (iGAS) in young children in the Netherlands, 2022.
de Gier B, Marchal N, de Beer-Schuurman I, Te Wierik M, Hooiveld M, ISIS-AR Study Group, GAS Study group, de Melker HE, van Sorge NM, Members of the GAS study group, Members of the ISIS-AR study group
In 2022, a sevenfold increase in the number of notifiable invasive Streptococcus pyogenes (iGAS) infections among children aged 0-5 years was observed in the Netherlands compared with pre-COVID-19 pandemic years. Of 42 cases in this age group, seven had preceding or coinciding varicella zoster infections, nine were fatal. This increase is not attributable to a specific emm type. Vigilance for clinical deterioration as iGAS sign is warranted in young children, especially those with varicella zost...
Abstract
Cited 3 times since 2023 (1 per year)
source: EuropePMC
European heart journal,
Volume 44, Issue 2, 1 1 2023, Pages 159-161
Guideline-based use of cardiac imaging for chronic coronary syndromes.
van der Bijl P, Stassen J, Bax JJ
Abstract
Cited 11 times since 2023 (3.7 per year)
source: EuropePMC
Clinical and translational allergy,
Volume 13, Issue 1, 1 1 2023, Pages e12221
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease.
Achten R, Thijs J, van der Wal M, van Luijk C, van Luin M, El Amrani M, Knol E, Delemarre E, Jager CDH, de Graaf M, Bakker D, de Boer J, van Wijk F, de Bruin-Weller M
Background: The patho-mechanism of ocular surface disease (OSD) in dupilumab-treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity of OSD during dupilumab treatment in AD patients. Methods: This prospective study included dupilumab-treated moderate-to-severe AD patients who were seen by a dermatologist and an ophthalmologist before the start of dupilumab (baseline), and afte...
Abstract
Cited 9 times since 2023 (3 per year)
source: EuropePMC
Clinical and translational allergy,
Volume 13, Issue 1, 1 1 2023, Pages e12219
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis.
Spekhorst LS, de Graaf M, van der Rijst LP, Zuithoff NPA, Schweizer RC, Kamsteeg M, Haeck I, van Lynden-van Nes AMT, van Lumig P, Romeijn GLE, Schuttelaar ML, de Bruin-Weller MS
Abstract
Cited 1 times since 2023 (0.3 per year)
source: EuropePMC
Revista latino-americana de enfermagem,
Volume 31, 1 1 2023, Pages e3923
Effect of the coughing technique during subcutaneous heparin injection on pain severity and individual satisfaction.
Yılmaz D, Ayhan D, Yılmaz DU, Düzgün F
to examine the effect of the medium intensity coughing technique during subcutaneous low molecular weight heparin injection on pain severity and individual satisfaction in general surgery patients. the prospective, quasi-experimental study included 100 patients who had been prescribed a subcutaneous low molecular weight heparin injection once in 24 hours. Each patient received two injections by the same researcher, one using the standard injection technique with medium intensity coughing techniq...
Abstract
Cited 19 times since 2022 (6.4 per year)
source: EuropePMC
Circulation. Genomic and precision medicine,
Volume 16, Issue 1, 29 5 2022, Pages e003672
Variant Location Is a Novel Risk Factor for Individuals With Arrhythmogenic Cardiomyopathy Due to a Desmoplakin (<i>DSP</i>) Truncating Variant.
Hoorntje ET, Burns C, Marsili L, Corden B, Parikh VN, Te Meerman GJ, Gray B, Adiyaman A, Bagnall RD, Barge-Schaapveld DQCM, van den Berg MP, Bootsma M, Bosman LP, Correnti G, Duflou J, Eppinga RN, Fatkin D, Fietz M, Haan E, Jongbloed JDH, Hauer AD, Lam L, van Lint FHM, Lota A, Marcelis C, McCarthy HJ, van Mil AM, Oldenburg RA, Pachter N, Planken RN, Reuter C, Semsarian C, van der Smagt JJ, Thompson T, Vohra J, Volders PGA, van Waning JI, Whiffin N, van den Wijngaard A, Amin AS, Wilde AAM, van Woerden G, Yeates L, Zentner D, Ashley EA, Wheeler MT, Ware JS, van Tintelen JP, Ingles J
Background: Truncating variants in desmoplakin (DSPtv) are an important cause of arrhythmogenic cardiomyopathy; however the genetic architecture and genotype-specific risk factors are incompletely understood. We evaluated phenotype, risk factors for ventricular arrhythmias, and underlying genetics of DSPtv cardiomyopathy. Methods: Individuals with DSPtv and any cardiac phenotype, and their gene-positive family members were included from multiple international centers. Clinical data and family hi...
Abstract
Cited 12 times since 2022 (4 per year)
source: EuropePMC
Journal of clinical medicine,
Volume 12, Issue 1, 29 5 2022, Pages 272
Are Thoracic Aortic Aneurysm Patients at Increased Risk for Cardiovascular Diseases?
Dolmaci OB, El Mathari S, Driessen AHG, Klautz RJM, Poelmann RE, Lindeman JHN, Grewal N
Objectives: Abdominal aortic aneurysms are associated with a sharply increased cardiovascular risk. Cardiovascular risk management is therefore recommended in prevailing guidelines for abdominal aneurysm patients. It has been hypothesized that associated risk relates to loss of aortic compliance. If this hypothesis is correct, observations for abdominal aneurysms would also apply to thoracic aortic aneurysms. The objective of this study is to test whether thoracic aneurysms are also associated w...
Abstract
Cited 5 times since 2022 (1.7 per year)
source: EuropePMC
Health and quality of life outcomes,
Volume 20, Issue 1, 29 5 2022, Pages 171
Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer.
Ripping TM, Rammant E, Witjes JA, Aaronson NK, van Hemelrijck M, van Hoogstraten LMC, BlaZIB study group, Kiemeney LA, Aben KKH
Background: Quality of Life (QoL) of bladder cancer patients has been largely neglected. This is partly due to the lack of well-validated QoL questionnaires. The aim of this study is to examine the structural validity, reliability (i.e., internal consistency and test-retest reliability), construct validity (i.e., divergent validity and known group validity) and responsiveness of the Dutch version of the European Organisation for Research and Treatment of Cancer QoL questionnaire for muscle invas...
Abstract
Cited 3 times since 2022 (1 per year)
source: EuropePMC
Epilepsy research,
Volume 190, 28 4 2022, Pages 107072
Corpus callosum thickness: A predictive factor for the first drug efficiency of self-limited epilepsy with centrotemporal spikes (selects)?
Dedeoglu Ö, Altaş H, Yılmaz D, Gürkaş E, Gülleroğlu B, Ekşioğlu S, Çıtak Kurt N
Objective: To investigate the existence of a possible linkage between the thickness of corpus callosum (CC) regions and the first antiepileptic drug response in patients with Selects. Materials and methods: CC thickness of 68 patients with Selects and 42 healthy controls between 4 and 12 years of age were measured using brain magnetic resonance imaging (MRI). Clinical and EEG features of newly diagnosed Selects patients were recorded. Patients were divided into two groups: good-response (patient...
Abstract
Cited 31 times since 2022 (10.4 per year)
source: EuropePMC
JACC. Cardiovascular interventions,
Volume 16, Issue 2, 28 4 2022, Pages 140-151
Staging Heart Failure Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.
Stolz L, Doldi PM, Orban M, Karam N, Puscas T, Wild MG, Popescu A, von Bardeleben RS, Iliadis C, Baldus S, Adamo M, Thiele H, Besler C, Unterhuber M, Ruf T, Pfister R, Higuchi S, Koell B, Giannini C, Petronio A, Kassar M, Weckbach LT, Butter C, Stocker TJ, Neuss M, Melica B, Braun D, Windecker S, Massberg S, Praz F, Näbauer M, Kalbacher D, Lurz P, Metra M, Bax JJ, Hausleiter J, EuroSMR Investigators
Background: Secondary mitral regurgitation (SMR) is a progressive disease with characteristic pathophysiological changes that may influence prognosis. Although the staging of SMR patients suffering from heart failure with reduced ejection fraction (HFrEF) according to extramitral cardiac involvement has prognostic value in medically treated patients, such data are so far lacking for edge-to-edge mitral valve repair (M-TEER). Objectives: This study sought to classify M-TEER patients into disease...
Abstract
Cited 6 times since 2022 (2 per year)
source: EuropePMC
International journal of cardiology,
Volume 374, 28 4 2022, Pages 79-82
Right ventricular strain in Fabry disease: Prognostic implications.
Meucci MC, Lillo R, Mango F, Lombardo A, Lanza GA, Parisi V, Grandinetti M, Massetti M, Ajmone Marsan N, Crea F, Graziani F
Introduction: Left ventricular (LV) hypertrophy is the main feature of cardiac involvement in Anderson-Fabry disease (FD), but the right ventricle (RV) is also frequently affected. Previous studies failed to demonstrate an independent association between conventional parameters of RV performance and outcomes in FD. Nevertheless, if RV free wall strain (RV-FWS), assessed by 2D speckle tracking analysis, may provide a better prognostication is currently unknown. Methods: We retrospectively evaluat...
Abstract
Cited 43 times since 2022 (14.5 per year)
source: EuropePMC
Brain, behavior, and immunity,
Volume 109, 28 4 2022, Pages 1-22
Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis.
Schepers M, Paes D, Tiane A, Rombaut B, Piccart E, van Veggel L, Gervois P, Wolfs E, Lambrichts I, Brullo C, Bruno O, Fedele E, Ricciarelli R, Ffrench-Constant C, Bechler ME, van Schaik P, Baron W, Lefevere E, Wasner K, Grünewald A, Verfaillie C, Baeten P, Broux B, Wieringa P, Hellings N, Prickaerts J, Vanmierlo T
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by focal inflammatory lesions and prominent demyelination. Even though the currently available therapies are effective in treating the initial stages of disease, they are unable to halt or reverse disease progression into the chronic progressive stage. Thus far, no repair-inducing treatments are available for progressive MS patients. Hence, there is an urgent need for the development of new...
Abstract
Cited 14 times since 2022 (4.7 per year)
source: EuropePMC
Circulation,
Volume 147, Issue 10, 27 4 2022, Pages 798-811
The MIDA-Q Mortality Risk Score: A Quantitative Prognostic Tool for the Mitral Valve Prolapse Spectrum.
Essayagh B, Benfari G, Antoine C, Grigioni F, Le Tourneau T, Roussel JC, Bax JJ, Delgado V, Ajmone Marsan N, van Wijngaarden A, Tribouilloy C, Rusinaru D, Hochstadt A, Topilsky Y, Topilsky Y, Thapa P, Michelena HI, Enriquez-Sarano M
Background: Mitral valve prolapse (MVP) is responsible for a considerable disease burden but is widely heterogeneous. The lack of a comprehensive prognostic instrument covering the entire MVP spectrum, encompassing the quantified consequent degenerative mitral regurgitation (DMR), hinders clinical management and therapeutic trials. Methods: The new Mitral Regurgitation International Database Quantitative (MIDA-Q) registry enrolled 8187 consecutive patients (ages 63±16 years, 47% women, follow-up...
Abstract
Cited 8 times since 2022 (2.7 per year)
source: EuropePMC
Molecular imaging and biology,
Volume 25, Issue 1, 27 4 2022, Pages 228-239
Data-Driven Identification of Targets for Fluorescence-Guided Surgery in Non-Small Cell Lung Cancer.
Meijer RPJ, Neijenhuis LKA, Zeilstra AP, Roerink SF, Bhairosingh SS, Hilling DE, Mieog JSD, Kuppen PJK, Sier CFM, Braun J, Burggraaf J, Vahrmeijer AL, Cohen D, Hutteman M
Purpose: Intraoperative identification of lung tumors can be challenging. Tumor-targeted fluorescence-guided surgery can provide surgeons with a tool for real-time intraoperative tumor detection. This study evaluated cell surface biomarkers, partially selected via data-driven selection software, as potential targets for fluorescence-guided surgery in non-small cell lung cancers: adenocarcinomas (ADC), adenocarcinomas in situ (AIS), and squamous cell carcinomas (SCC). Procedures: Formalin-fixed p...
Abstract
Cited 42 times since 2022 (14.1 per year)
source: EuropePMC
Genome biology,
Volume 23, Issue 1, 27 4 2022, Pages 268
Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis.
Kanoni S, Graham SE, Wang Y, Surakka I, Ramdas S, Zhu X, Clarke SL, Bhatti KF, Vedantam S, Winkler TW, Locke AE, Marouli E, Zajac GJM, Wu KH, Ntalla I, Hui Q, Klarin D, Hilliard AT, Wang Z, Xue C, Thorleifsson G, Helgadottir A, Gudbjartsson DF, Holm H, Olafsson I, Hwang MY, Han S, Akiyama M, Sakaue S, Terao C, Kanai M, Zhou W, Brumpton BM, Rasheed H, Havulinna AS, Veturi Y, Pacheco JA, Rosenthal EA, Lingren T, Feng Q, Kullo IJ, Narita A, Takayama J, Martin HC, Hunt KA, Trivedi B, Haessler J, Giulianini F, Bradford Y, Miller JE, Campbell A, Lin K, Millwood IY, Rasheed A, Hindy G, Faul JD, Zhao W, Weir DR, Turman C, Huang H, Graff M, Choudhury A, Sengupta D, Mahajan A, Brown MR, Zhang W, Yu K, Schmidt EM, Pandit A, Gustafsson S, Yin X, Luan J, Zhao JH, Matsuda F, Jang HM, Yoon K, Medina-Gomez C, Pitsillides A, Hottenga JJ, Wood AR, Ji Y, Gao Z, Haworth S, Yousri NA, Mitchell RE, Chai JF, Aadahl M, Bjerregaard AA, Yao J, Manichaikul A, Hwu CM, Hung YJ, Warren HR, Ramirez J, Bork-Jensen J, Kårhus LL, Goel A, Saba
Background: Genetic variants within nearly 1000 loci are known to contribute to modulation of blood lipid levels. However, the biological pathways underlying these associations are frequently unknown, limiting understanding of these findings and hindering downstream translational efforts such as drug target discovery. Results: To expand our understanding of the underlying biological pathways and mechanisms controlling blood lipid levels, we leverage a large multi-ancestry meta-analysis (N = 1,65...
Abstract
